Wolfgang Jost discusses the latest treatment and diagnosis approaches in cervical dystonia.
FILMED AT THE INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS (IPMDS), JUNE 2016
WHAT RECENT ADVANCES HAVE BEEN MADE IN THE USE OF BOTULINUM TOXIN IN THE TREATMENT OF CERVICAL DYSTONIA?
00:10 – I think there are two important things. One is the use of ultrasound, so we need meanwhile ultrasound in every patient. And the second thing is a new classification, the so called COL-CAP concept.
WHAT ARE THE MAJOR UNMET NEEDS IN THE TREATMENT OF CERVICAL DYSTONIA?
00:30 – We have to differentiate between the agonist, the antagonist and the compensatory muscle. That’s very useful to treat the patients. The second thing is we need a new score because the TWISTER is not compatible with the COL-CAP concept.
WHAT ARE THE CHALLENGES OF THE DIFFERENTIAL DIAGNOSIS OF CERVICAL DYSTONIA?
00:53 – The challenge is to differentiate between normal cervical dystonia and more complex forms. And I think at the moment we are not able to differentiate with our tools both forms.
WHAT NEW TREATMENT AND DIFFERENTIATION APPROACHES ARE BEING PRESENTED TODAY?
01:11 – Today we demonstrate a new concept with C2 as a fixed point with the differentiation of caput and collum, so you can turn the head or you can turn the neck. And the second important thing is the use of ultrasound to look for especially deeper muscles.
Share this Video
Related Videos In Movement Disorders
Francisco Cardoso: International Parkinson and Movement Disorder Society (MDS) – President update
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals, who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. touchNEUROLOGY caught up with the MDS President, Prof. Francisco Cardoso, to discuss the upcoming […]
Donald Gilbert, AAN 2022: Ecopipam investigated for the treatment of children and adolescents with Tourette’s syndrome – Phase 2b results
Ecopipam is an investigational first-in-class drug being evaluated for the treatment of children and adolescents with Tourette’s syndrome. Prof. Donald Gilbert (Cincinnati Children’s Hospital Medical Centre, Cincinnati, OH, USA) discusses the randomised, double-blind, placebo-controlled phase 2b study investigating ecopipam. The abstract entitled ‘Ecopipam in Children and Adolescents with Tourette Syndrome: Results from a Randomized, Double-Blind, […]
Davide Martino, AAN 2022: Functional neurological symptoms in the time of COVID-19 – Learning from tic-like behaviours
Functional neurological symptoms have been observed in young people globally during the COVID-19 pandemic, presenting with rapid onset of complex motor and vocal tic-like behaviours. Dr Davide Martino (Hotchkiss Brain Institute, University of Calgary, Calgary, Canada) discusses the rise in tic-like behaviour during the COVID-19 pandemic and what registry studies taught us about interventions of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!